Informationstyper: PRM

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were passed with the required majority.

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previously received approval by the Russian Ethics Committee. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previously received approval by the Spanish Ethics Committee. With both regulatory and ethical approval all prerequisites to start the trial in Spain are met. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019.

The Company announces that the investigational drug (two doses of STA363 and placebo) now is manufactured and quality assured by our partner APL.

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from the RA is conditioned final approval by the Ethics Committee, which has not yet finalized the review of the application. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

The company can announce that an additional important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities in Spain and previously in Russia and the Netherlands, the three countries in which the Company’s phase 2b study is planned to be conducted.

The company can announce that an important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities and ethical committees in the Netherlands and previously in Russia, two out of three countries in which the Company’s phase 2b study is planned to be conducted. Application to Spanish authorities is estimated during March.

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North Growth Market. The share is traded under the ticker “STABL” with the ISIN code SE0013513652 and the warrant is traded under the ticker ”STABL TO1” with the ISIN code SE0013748381.

Stayble Therapeutics AB (”Stayble” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company’s share on Nasdaq First North Growth Market with first day of trading March 9.

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on Nasdaq First North Growth Market (”Nasdaq First North”). First day of trading on Nadaq First North is set to March 9, 2020.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

The subscribtion period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new units issue prior to the intended listing on Nasdaq First North Growth Market ended tuesday February 18, 2020. The new issue of approximately SEK 35 million was subscribed for a total amount of  SEK 153 million, corresponding to 436%. In connection to the new issue, Stayble received around 830 new shareholders.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

The subscription period to subscribe for units in the intended initial public offering from Stayble Therapeutics AB (“Stayble” or the “Company”) ends tomorrow, february 18. Subscription for units through some custodians may close tonight at 23:59

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Today on February 4, 2020, the subscription period to subscribe for units in the intended initial public offering from Stayble Therapeutics AB (“Stayble” or the “Company”) commences and continues until February 18, 2020.  The Company invites potential investors to attend investment meetings at Stayble in Gothenburg February 11, Mangold in Malmö february 12 and Mangold in Stockholm February 13.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Stayble Therapeutics AB (“Stayble” or the “Company”) has composed a prospectus for the issuance of units to institutional investors and the public in Sweden in connection with the intended listing of  the Company’s share on Nasdaq First North Growth Market (“Nasdaq First North”). The prospectus, approved and registered with the Swedish Financial Supervisory Authority today January 31, 2020, is available on the Company’s webpage (www.staybletherapeutics.com) and on Mangold Fondkommission’s webpage (www.mangold.se). The prospectus will also be made available on the Swedish Financial Supervisory Authority´s webpage (www.fi.se).

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

The Board of Directors in Stayble Therapeutics AB (“Stayble” or “the Company”) announces today their intention to list the Company’s shares on Nasdaq First North Growth Market (“Nasdaq First North”). In connection with the listing, the Company carries out a new unit issue of  approximately SEK 35 million, before deduction of transaction costs, where each unit consists of one share and one warrant free of charge (“the Offering”).